Honest administration can bring peace, stability to J&K

New Delhi, Mar 25: The government is likely to agree an economic stimulus package of more than Rs 1.5 lakh crore ($19.6 billion) to fight a downturn in the country that is currently locked down to stem the spread of coronavirus, two sources familiar with the matter told news agency.
The government has not yet finalised the package and discussions are ongoing between Prime Minister Narendra Modi's office, the finance ministry, and Reserve Bank of India (RBI), said both the sources, who asked not to be named as the matter was still under discussion.

One of the sources, a senior government official, said the stimulus plan could be as large as Rs 2.3 lakh crore, but final numbers were still in discussion.

The package could be announced by the end of the week, both sources added.

Warangal, Jul 22: Amid the COVID-19 pandemic, an outlet in Telangana's Warangal has started selling 'anti-corona' tea. The tea has become an instant hit with the locals as the beverage is laced with natural immunity-boosting ingredients.

"We sell tea named 'anti-corona'. It has natural immunity-boosting ingredients such as ginger, black pepper, cinnamon powder, among other things. A mixture of these ingredients boosts our immunity," Shiva, the owner of the tea shop said.

"Better immunity is needed to fight the coronavirus infection in the body. So we have started preparing this tea and selling it during the coronavirus pandemic," he added.

Prabhakar, a customer at the tea stall said, the tea was a "corona special tea," and it has Ayurvedic mixtures which help to boost the immunity of the human body.

"The tea is prepared after adding the Ayurveda mixtures to milk. This is good for your health. I, along with my family members and friends, come here every day. We drink this tea thrice a day," Prabhakar added.

According to the Union Health Ministry, there are 46,274 COVID-19 cases in Telangana. Meanwhile, India's coronavirus count stood at 11,92,915 on Wednesday morning.

New Delhi, Jul 3: In a significant step, ICMR has partnered with Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine). It is the first indigenous vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the Government, says ICMR in a statement.

The vaccine is derived from a strain of SARS-CoV-z isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine.

In a letter to the institutes that will be involved in the trails of the vaccine, ICMR has said

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials. BBIL is working expeditiously to meet the target. However, final outcome will depend on the cooperation of all clinical trial sites involved in this project. you have been chosen as a clinical trial site of the BBV152 COVID vaccine. ln view of the public health emergency due to COVID-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast track all approvals related to initiation of the clinical trial and ensure that the subject enrollment is initiated no later than 7th July 2020."

The ICMR also asked the institutes to comply with the order, "Kindly note that non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on the highest priority and meet the given timelines without any lapse."

The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.